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Abstract
Our lab previously demonstrated that expression of the lineage-determining transcription
factor SOX17 in human embryonic stem cells was sufficient to specify stable definitive
endoderm progenitors (DEPs). The current study was aimed at generating pancreatic
precursors from SOX17-DEPs through controlled expression of the transcription factor
NGN3. We generated hESC lines with inducible SOX17 and NGN3 and compared the
effects of high and low levels of NGN3 expression. NGN3 expression in DEPs induced
markers of pancreatic differentiation (PAX4, PAX6, NKX6.1, ISL1). While high NGN3
expression induced the β cell marker PDX1, low NGN3 expression induced the δ cell
markers (CCKBR, somatostatin) within 12 days. We subsequently aimed to guide
SOX17-NGN3 precursors to mature endocrine cells by culture in media pre-conditioned
by multipotent stromal cells previously screened for islet regenerative capacity following
transplantation in vivo. However, endocrine maturation was not observed. These findings
demonstrate the precision required to direct β cell differentiation.
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CHAPTER 1:
General Introduction

2
1.1.

Diabetes Mellitus
Diabetes Mellitus (DM) is a metabolic disorder characterized by hyperglycemia

or high blood glucose levels. Elevated blood glucose concentrations in diabetic patients
are due to inadequate synthesis and secretion of insulin from the pancreas (insulin
deficiency) or desensitization of insulin signaling response (insulin resistance) [1].
Insulin is a hormone that maintains glucose homeostasis: it regulates liver, skeletal
muscle and adipose tissue to absorb glucose from the blood thereby reducing postprandial blood glucose levels [2]. Other symptoms of diabetes include increased urination
(polyuria), increased thirst (polydipsia), increased hunger (polypaghia), and weight loss
[3]. Currently, diabetes is an emerging epidemic that is expected to affect more than 360
million people worldwide by 2030 [4]. The aging population of North America and rising
obesity rates further exacerbate the prevalence of the disease. Importantly, diabetes is a
risk factor for many vascular diseases such as stroke, limb ischemia and heart attack
along with retinopathy and neuropathic disorders, which will take an enormous toll on
global healthcare costs in the near future.

1.1.1. Types of Diabetes Mellitus
Type I Diabetes Mellitus (T1DM) is caused by auto-immune destruction of
insulin-secreting β cells of the islets of Langerhans in the pancreas resulting in absolute
insulin deficiency. Major players of this auto-immune reaction are autoantibody
producing B cells [5], CD4+ T helper cells [6], CD8+ T cells [7], and monocytes and
macrophages of the innate immune system [8].

Onset of T1DM is early, usually

diagnosed in children and adolescents. Patients afflicted with this condition are entirely
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dependent upon exogenous sources of insulin for maintaining glucose homeostasis. If
untreated T1DM is fatal; however, despite insulin supplementation children diagnosed
with T1DM by age 10 are estimated to have a life expectancy 18 years shorter than the
non-diabetic population [9].
In contrast, Type II Diabetes Mellitus (T2DM) is the result of insufficient
secretion of insulin by β cells due to insulin resistance [10]. Insulin resistance is
characterized by the decreased sensitivity of cells to insulin. Insulin resistant cells fail to
adequately absorb circulating insulin causing hyperglycemia. β cells respond to decreased
insulin

sensitivity

by

increased

insulin

secretion

resulting

in

compensatory

hyperinsulinemia but are still unable to overcome insulin resistance [10]. This condition
is known as relative insulin deficiency, a hallmark of T2DM. During late stages of
T2DM, β cell toxicity and exhaustion reduces insulin secretion, leading to insulin
dependence [11].
Unlike T1DM patients that depend solely on exogenous insulin injections, T2DM
can be managed using drug-based treatment options combined with life-style adjustments
such as increased physical activity. Drugs that act to lower blood glucose levels or to
enhance insulin secretion by β cells are the two primary treatment options. Metformin,
one of the most commonly prescribed medications for T2DM, acts by suppressing
glucose production and systemic release by the liver (hepatic gluconeogenesis), and
enhances insulin sensitivity in muscle and adipose tissue, thereby lowering blood glucose
[12]. Another class of anti-diabetic drug, sulfonylurea derivatives, acts to enhance insulin
secretion by β cells to compensate for insulin resistance in the body [12]. Despite these
treatment options, the relative risk of death for T2DM is two times higher than the non-
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diabetic population, resulting in significant reduction in life-expectancy of individuals
with T2DM [13].

1.2

Pancreas Biology
In mammals, the pancreas is located in the abdomen posterior to the stomach

attaching to the duodenum. It is an essential organ for nutrient metabolism consisting of
exocrine and endocrine components.

1.2.1

The Exocrine Pancreas
By mass the pancreas is primarily an exocrine organ; approximately 98% of the

pancreas is composed of either acinar or ductal cells whose primary function is nutrient
digestion. The cells are filled with secretory granules containing precursor proteases that
are activated once released into the duodenum along with pancreatic lipase and amylase
[14]. The pancreas responds to signals from the duodenum and secretes digestive
enzymes along with bicarbonate ions to neutralize the acidic chyme released from the
stomach [14].

1.2.2.

The Endocrine Pancreas
Approximately 2% of pancreas mass is composed of endocrine cells organized in

small highly vascularized structures called islets of Langerhans. The primary function of
the islets of Langerhans is maintaining blood glucose homeostasis.

There are five

different types of endocrine cells within islets: α cells that secrete glucagon, β cells that
secrete insulin, δ cells that secrete somatostatin, F cells (or PP cells) that secrete the
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hormone pancreatic polypeptide (PP) and ε cells that secrete ghrelin. In mice, α cells are
located in the periphery of the islets forming a cortex of cells surrounding the more
numerous β cells, which are located in the islet core [15] (Figure 1.1). In contrast, in
humans β cells do not reside at the center of the islets but are intermingled with α and δ
cells [15] (Figure 1.1).

1.2.2.1 α cells
α cells are the second most abundant cells of the islets of Langerhans in both mice
and humans [15].

Their primary function is to synthesize pro-glucagon, which is

proteolytically processed and secreted as the hormone glucagon. Glucagon is a 29 amino
acid peptide that regulates blood glucose concentration by promoting glycogenolysis and
gluconeogenesis in the liver [16], processes that increase plasma glucose levels.
Glucagon acts on cells via G protein-coupled receptors [17], which have been identified
in multiple tissues including liver, kidney, intestines, pancreas and brain [18].
Glucagon is synthesized as a much larger precursor peptide called
preproglucagon. Upon modification in the rough endoplasmic reticulum (RER) it is
processed to proglucagon and it is further modified to functional glucagon by subtilisinlike proprotein convertase 2 (PC2) [19]. The principle factor that regulates glucagon
secretion is serum glucose concentration [20], with the hyperglycemic state being
inhibitory and hypoglycemic state being stimulatory. Peptides such as acetylcholine [21],
epinephrine [22] and norepinephrine [23] have been shown to stimulate glucagon
secretion, while somatostatin and insulin secretion have an inhibitory effect on glucagon
secretion [24,25].

6

Figure 1.1. Schematic representation of cellular organization and composition of
murine and human islets of Langerhans. In murine islets β cells are organized in the
islet core and make up approximately 77% of all endocrine cells, while α cells make up
approximately 18% of the islet and are located in the islet periphery along with other
endocrine cells [15]. In contrast, human islets lack an organized core with cells
intermingled with each other, and are composed of roughly 50% β cells, 35% α cells and
10% δ cells [15].
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1.2.2.2 β cells
β cells are the most abundant endocrine cells of the pancreas. In mice,
approximately 77% of all islet endocrine cells are β cells, while in humans islet endocrine
cells are composed of 50% β cells and a greater proportion of α and δ cells than mice
[15]. β cells secrete insulin, proinsulin, C-peptide and amylin into the bloodstream. The
function of β cells is to maintain glucose homeostasis. β cells secrete insulin in response
to postprandial blood glucose concentration, and in turn insulin enables body cells to
absorb and metabolize circulating glucose to bring glucose concentrations back to basal
levels [26]. The biosynthesis of insulin is highly regulated by glucose. Studies have
shown that proinsulin gene transcription and biosynthesis positively correlates with
plasma glucose levels [27]. This is indicative of the adaptive response to elevation of
glucose in the blood.
The insulin gene is located on chromosome 11 in humans. The full insulin
transcript codes for the 110 amino acid preproinsulin [28], which is cleaved in the ER to
generate the 86 amino acid proinsulin [29]. Proinsulin is transported from the ER to the
Golgi apparatus and subsequently into immature secretory vesicles where it is processed
to insulin and C-peptide by coordinated action of proprotein convertase (PC) 2 and PC
1/3 [30]. Within the proinsulin peptide, amino acids 1 to 30 constitute the B chain of
insulin, amino acids 66 to 86 constitute the A chain of insulin, and residues 31 to 65 form
the cleaved C-peptide moiety [31]. The monomeric insulin consists of the A chain and B
chain linked together by disulfide bridges. Thus, insulin and C-peptide are secreted in
equimolar amounts by β cells. Proinsulin may be is also secreted into the blood stream
and has greater half-life [32], but a much lower biological potency than insulin [33].
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Although β cells respond to many other nutrients in the circulation, including
amino acids and fatty acids, the extent of insulin secretion in humans is much greater in
response to glucose when compared with other stimuli. In β cells, glucose metabolites
trigger insulin secretion into the bloodstream. Glucose enters β cells by the glucose
transporter 2 (GLUT2) and is phosphorylated by glucokinase (GCK), and initiates
glycolysis and ATP production [34]. Elevation of the cytosolic ATP to ADP ratio blocks
ATP-dependent K+ channels, which in turn results in membrane depolarization and
subsequent opening of voltage gated Ca+ channels [35]. Increase cytosolic Ca+2
concentrations represents the main trigger initiating the exocytosis of insulin, proinsulin
and c-peptide containing vesicles [35]. This process is termed glucose-mediated insulin
secretion (Figure 1.2).

1.2.2.3 δ cells
In humans, δ cells comprise roughly 8-12% of all islet endocrine cells [15] and
are responsible for the synthesis and secretion of the hormone somatostatin. Apart from
the pancreas, somatostatin is also secreted by δ cells in the stomach and neuroendocrine
cells in the periventricular nucleus of the hypothalamus. Functional forms of somatostatin
exist as a 28 amino acid peptide or a 14 amino acid peptide. Somatostatin-14 is the Cterminal portion of somatostatin-28, and represents the primary isoform responsible for
its physiological function [36]. δ cells predominately secrete the 14 amino acid form,
while intestinal mucosal cells secrete the 28 amino acid form [37].
Somatostatin secretion is regulated by glucose [38], glucagon-like peptide 1
(GLP-1) [39], and gastrin [40]. δ cells express Ryanodine Receptor 3 (RyR3), a Ca+2-
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Figure 1.2. Schematic representation of glucose-mediated insulin secretion in β cells.
Glucose enters β cells via GLUT2, and upon its metabolism the cytosolic ATP:ADP ratio
increases resulting in inhibition of K+ channels. Increased cytosolic concentration of K+
results in plasma membrane depolarization and subsequent activation of voltage-gated
Ca+2 channels. Cellular Ca+2 influx initiates the exocytosis of insulin containing vesicles.
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channel shown to be responsible for glucose-mediated somatostatin secretion via Ca+2induced Ca+2 release mechanism. Glucose metabolites induce Ca+2 secretion from
internal ER stores, and the resulting increase of cytosolic Ca+2 concentration leads to
activation of RyR3 Ca+2 channels further increasing the cytosolic Ca+2 concentration,
which activates exocytosis of somatostatin secretory vesicles [38]. δ cells also express
Cholycytokinin (CCK) B Receptor (CCKBR), which upon binding with CCK and Gastrin
promotes somatostatin secretion [40]. Somatostatin inhibits the secretion of several
hormones such as growth hormone (GH) [41] and thyroid stimulating hormone (TSH)
[42] from the anterior pituitary, pancreatic hormones [43], and gastro intestinal peptide
hormones such as vasoactive intestinal peptide (VIP) and gastrin [44]. Somatostatin
receptors (SSTRs) coupled to Gi/o proteins have been identified in gut endocrine G cells
[45], and pancreatic endocrine α and β cells [46]. Activation of SSTRs inhibits hormonal
secretion by suppressing cAMP and Ca+2 influx via voltage-gated Ca+2 channels, thereby
directly reducing exocytosis [47]. Importantly, somatostatin activity is known to decrease
glucose-stimulated insulin secretion in β cells.

1.2.2.4 F cells
F cells (or PP cells) constitute a very small portion of the human islets of
Langerhans [15]. Their primary function is the synthesis and secretion of PP, a hormone
known to regulate gastrointestinal motility and secretions. PP acts to reduce the rate of
gastric emptying [48], gall bladder emptying [49], and pancreatic exocrine secretion [50].
PP secretion is promoted by insulin-induced hypoglycemia and direct vagal nerve
stimulation [51]. Hyperglycemia inhibits PP secretion [52].
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1.2.2.5 ε cells
ε cells synthesize and secrete ghrelin, a hormone which is also produced by D1
cells residing in the fundus of the stomach. Ghrelin is a 28 amino acid peptide that acts as
a hunger-inducing hormone by activating the mesolimbic cholinergic-dopaminergic
circuitry that reinforces rewards such as food [53,54]. Therefore, it is suggested that
ghrelin antagonists could be a potential treatment for obesity. Furthermore, gherlin has
been shown promote the release of GH via activation of the G-protein coupled receptor
GSH-R1a in the anterior pituitary [55]. Ghrelin secretion is primarily regulated by food
intake.

1.3.

Pancreatic Development
During the blastula stage of development, the embryo is composed of a single

layer of epiblast cells which become organized into a three-layered structure during
gastrulation. Gastrulation occurs when epiblast cells around the newly formed primitive
streak undergo epiblast to mesenchymal transition and ingress through the primitive
streak giving rise to three germ layers [56]. Gastrulation is followed by organogenesis,
where each of the three germ layers, the ectoderm, mesoderm and endoderm, gives rise to
specific tissues and organs. The ectoderm gives rise to epidermis and cells of the nervous
system [57], the mesoderm gives rise to the notochord, muscle, bone, cartilage and other
connective tissues [58-60], and the endoderm gives rise to the respiratory system and
organs associated with the digestive system such as the pancreas [61].
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1.3.1. Formation of the Pancreas from Definitive Endoderm.
Prior to organogenesis, the endoderm undergoes extensive patterning along the
anterior-posterior axis. The definitive endoderm gives rise to the primitive gut tube,
which becomes specified into distinct organ domains along the dorsal-ventral and
anterior-posterior axes into foregut, midgut and hindgut in response to signaling events
initiated by the surrounding mesoderm [61]. Factors secreted by mesodermal tissues such
as the notochord including Activin and FGF2 allow for pancreas and liver fate
determination from the gut endoderm [61]. Both exocrine and endocrine components of
the pancreas arise from a common precursor population residing in the primitive gut [62].
In mice, the first morphological signs of pancreas formation occur at embryonic day (E)
9.0, when the pancreas emerges as two epithelial buds from opposite ends of the foregut
endoderm [63]. These buds contain multipotent pancreatic progenitor cells (MPCs) that
will ultimately give rise to all three pancreatic lineages [64]. Lineage-tracing experiments
have shown that MPCs retain the potential to develop all pancreatic lineages until E12.5.
Between E9.0 to E12.5 the MPCs residing in the ventral and dorsal pancreatic epithelia
proliferate and expand the progenitor population [65]. Both pancreatic buds also undergo
expansion during this period and invade the surrounding mesenchyme, forming a multilayered stratified epithelium. Between E11.5 and 12.5 the two buds merge together
during rotation of the gut [66]. At E12.5 the pancreas undergoes branching
morphogenesis forming tubular structures. At this stage the pancreas consists of two cell
types: the epithelial tips contain MPCs which eventually give rise to acinar progenitor
cells by E13.5, while the tubular or trunk regions are comprised of cells that will form
either ducts or endocrine cell types [66].
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Differentiation of endocrine pancreas cells is first seen in the dorsal bud, where
glucagon-positive cells emerge around E9.5, and insulin positive cells emerge around
E10.5 in both buds [67]. E12.5 to E15.5 is a period in which pancreas progenitors
undergo extensive proliferation and terminal differentiation into endocrine or acinar cell
fates [66]. Also during this phase of endocrine differentiation, the pancreatic endocrine
cells begin to organize into cell clusters, which eventually coalesce post-natally to form
islets.
Similar to mice, in humans, the pancreas forms from the fusion of dorsal and
ventral pre-pancreatic buds of the primitive gut. The dorsal pancreatic bud is first evident
morphologically at day 26 post-conception (dpc) and the fusion of the buds occurs by 56
dpc [68]. Endocrine differentiation appears to begin around 8 weeks post-conception
(wpc). Furthermore, human endocrine cells start coalescing into islet-like cell clusters
around 11-14 wpc [68], and undergo a final reorganization after 21 wpc with
intermingled β and α cells [69].

1.3.2. Role of Transcription Factors in Pancreatic Development
Transcription factors (TFs) are crucial components of gene regulatory network;
they interact with each other as well as other proteins to control mRNA and
consequentially, protein expression. During development TFs control the expression of
genes necessary for cell fate specification and cellular differentiation. The formation of
the pancreas depends on specific signaling events, which regulate TF activity. Cell typespecific regulatory networks, consisting of interactions between TFs and extrinsic signals,
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guide the pancreatic progenitor population in a context-dependent manner to their
programmed fate.

1.3.2.1 SOX17
Sex Determining Region Y (SRY) – High Mobility Group Box (HMG-box) 17
(SOX17) is part of a family of transcription factors involved in regulation of embryonic
development and cell fate determination. SOX17 belongs to the Sox-subgroup F along
with SOX7 and SOX18. The HMG-box is the DNA-binding domain composed of three
alpha helices separated by loops, a highly conserved domain among eukaryotic species
[70].
SOX17 is essential for the development of definitive endoderm: in Sox17
knockout mice the definitive endoderm is depleted and the embryonic gut and all its
associated organs fail to form [71]. Sox17 binds to the minor groove of DNA at the
ATTGT consensus motif and regulates the transcription of genes involved in definitive
endoderm specification during gastrulation [72]. The C-terminus of Sox17 has been
shown to bind to β-catenin, and this is important for transcription of several endodermal
genes including Hepatocyte Nuclear Factor (HNF) 1β, Forkhead box protein (FOX) A1
and FOXA2. [73].

1.3.2.2 Early Pancreatic Transcription Factors (HNF1β, HNF6, PDX1, SOX9 and
PTF1a)
The earliest transcription factors that mark the MPCs residing in the ventral and
dorsal pancreatic buds are HNF1β, HNF6, Pancreatic and Duodenal Homeobox 1
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(PDX1), SOX9 and Pancreas-specific Transcription Factor 1a (PTF1a) [66]. During
mouse development, Hnf1β is expressed in the foregut endoderm at E8 prior to the
formation of pancreatic endoderm [74], and at later stages of pancreatic development its
expression is maintained exclusively in duct cells [75]. Hnf1β regulates the expression of
Hnf6, which is an important regulator of Pdx1 expression, a key early pancreatic
progenitor marker [76]. It has been suggested that sequential activation of Hnf1β, Hnf6
and Pdx1 gives rise to pancreatic multipotent progenitor populations [76], whereas Sox9
is implicated with MPC proliferation [77].
Lineage tracing experiments in mice have demonstrated that Pdx1 expressing
multipotent cells give rise to all pancreatic cell types [78]. Pdx1 marks the pre-pancreatic
tissue of the endoderm since its expression is initiated at E8.5, prior to the morphological
changes associated with the development of the ventral and dorsal pancreatic buds [79].
Pdx1 is essential for early pancreatic development and precursor cell expansion. Pdx1null mice showed impaired pancreatic development by E10.5 and lack a pancreas at birth
[80]. At later stages of pancreatic development Pdx1 is expressed in β cells [81]. Apart
from the pancreas, Pdx1 is expressed in the other endoderm-derived endocrine cells such
as gastric enteroendocrine cells of the developing gut [82,83]. For example, G cells are
absent in Pdx1-null mice, suggesting that Pdx1 is important for the development of
gastrin-secreting cells [83].
Similar to Pdx1, pancreas-specific Sox9 knock-down results in loss of MPC
proliferation [78]. Sox9 has also been implicated in the maintenance of MPC identity
through direct regulation of key MPC genes including Hnf1β, FoxA2 and Hnf6 [84].
Another TF crucial for the commitment and expansion of MPCs is PTF1a. Ptf1a-
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deficient cells do not remain committed to the pancreatic fate and adopt an intestinal fate
in vivo [85]. Furthermore, Pdx1 and Ptf1a have the ability to guide duodenal precursors
to pancreatic fate when expressed ectopically [85].

1.3.2.3 NGN3
In early pancreatic development, MPCs have the potential to give rise to all three
pancreatic cell types including endocrine cells. Neurogenin 3 (NGN3), a basic helix loop
helix (bHLH) TF, is necessary for endocrine specification of MPCs. NGN3-positive
precursor cells give rise to all five pancreatic endocrine cell types [62]. Ngn3-null mice
are devoid of pancreatic endocrine cells but demonstrate normal acinar and ductal
development [86]. NGN3 directly induces the expression of other TFs that are important
for pancreatic endocrine differentiation, including paired-box containing gene (PAX) 4,
Insulinoma-associated 1 (INSM1) and regulatory factor X (RFX) 6 [87]. Expression of
Ngn3 occurs in a biphasic manner in the developing mouse pancreas: Ngn3 expression
first occurs at E9.5 and is downregulated by E10.5 and then Ngn3 expression peaks again
around E12.5 and diminishes permanently from pancreatic endocrine progenitors by E18
[88]. In contrast, the human embryonic pancreas demonstrates a single phase of NGN3
expression which is maintained from 8 wpc up to 21 wpc [89].

1.3.2.4 Additional Pancreatic Endocrine Transcriptional Factors
Following NGN3 activation, several downstream TFs are activated that guide
pancreatic endocrine progenitors to one of the five cell fates. Insm1 is expressed early in
the endocrine specification pathway and Pax4 is expressed shortly after and has a more
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specific role. This is supported by studies showing that Insm1-deficient mice demonstrate
a deficiency in all endocrine cell types [90], whereas Pax4-null mice only show
diminished numbers of β and δ cells, along with increased numbers of α and ε cells [91].
Thus, Pax4 serves to specify NGN3-positive progenitors to the β and δ cell fates, while
repressing the α and ε cell fates.
Another important TF that directs Ngn3-positive endocrine specifications is Arx.
Ngn3-positive progenitors express both Pax4 and Arx, but Pax4 expression restricts
endocrine progenitors to β and δ cell fates while Arx expression restricts them to α cell
fate [91]. This is supported by studies showing Arx-null mice having the opposite
phenotype of Pax4-null mice: complete loss of α cells but an increase in both β and δ cell
types [92]. In addition to enhancing the expression of certain TFs, repression of specific
TFs is required to maintain the phenotype of mature endocrine cells. For example, the
continual repression of Arx expression in β cells is important for the maintenance of β
cell phenotype and identity. The repression of Arx expression is maintained by Nkx2.2
and Nkx6.1 [93,94].
Following Pax4 expression, Pax6 plays an important role for further maturation
of α, β and δ cells. Pax6-null mice show a complete loss of α cells, and diminished
numbers of β and δ cells, and an increase in ghrelin-positive cells [95]. Pax6 expression
is maintained in mature α, β and δ cells and it serves to regulate insulin, glucagon and
somatostatin gene transcription [95].
Another late stage endocrine marker is NKX6.1, the expression of which is
downstream of NKX2.2. Studies investigating human endocrine progenitor cells have
shown that NKX6.1-positive precursors give rise to insulin-positive and somatostatin-

18
positive cells, while NKX6.1-negative precursors give rise to greater proportions of
glucagon-positive cells and lower proportion of β and δ cells [96]. This suggests that
NKX6.1-positive progenitors have the ability to adapt either β or δ cell fates at the
expense of the α cell fate. However, upon maturation NKX6.1 expression is maintained
exclusively in β cells [97]. Nkx2.2 has been shown in mice to be necessary for the
promotion of terminal β cell differentiation [98] and suppression of δ cell phenotype by
repressing somatostatin gene expression [99] (Figure 1.3).
β and δ cells have common regulators during development, and also show
common patterns of TF expression in mature cell types (Figure 1.3). For instance, PDX1
expression is restricted to mature β cells and a subpopulation of δ cells. In rat, Pdx1 and
Pax6 have been shown to bind to the upstream somatostatin enhancer to promote gene
transcription [100]. In β cells PDX1 directly binds to the insulin gene promoter resulting
in activation of gene expression [101]. Another mature endocrine TF, insulin gene
enhancer protein 1 (ISL1) enhances transcription of both insulin and somatostatin by
binding to insulin enhancer elements and the somatostatin promoter, respectively [102].
MafA and Nkx6.1 are considered hallmarks of the mature β cell phenotype since
they are uniquely expressed in β cells. These genes are also crucial for mature β cell
function. MafA-null mice show reduced transcription of insulin, Pdx1 and Glucose
transporter type 2 (Glut2) [94]. Similarly, Nkx6.1 directly controls the expression of
genes that maintain the β cells function, including Glut2, the proinsulin-to-insulin
convertase enzyme PC1, proteins associated with insulin protein folding and maturation
such as endoplasmic reticulum oxidorecutin 1-β (ERO1-β), and the islet-specific zinc
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Figure 1.3. Summary of transcription factor-mediated pancreatic endocrine
specification during mammalian development. NGN3 activates the transcription of
PAX4, which guides progenitor cells towards β and δ cell fates at the expense of other
endocrine cell fates. Downstream of PAX4, PAX6 also promotes β and δ cell phenotype
and its expression is maintained in both mature cell types. Whereas, NKX2.2 suppresses
δ cell specification and promotes terminal β cell differentiation. Consequentially, mature
δ cells do not express NKX2.2 and NKX6.1.
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transporter (ZnT-8) important for insulin secretion [97]. Nkx6.1-null mice show impaired
insulin biosynthesis and insulin secretion, and a rapid onset of hyperglycemia and
hypoinsulinemia [97].

1.4.

Stem Cells
Stem cells are primitive cells with the ability to differentiate into a mature

specialized cell types or self-renew and maintain their primitive phenotype [103]. There
are two main categories of stem cells: pluripotent stem cells, and adult stem cells.
Embryonic stem cells and induced pluripotent stem cells (iPSC - first derived from
murine fibroblast by ectopic expression of the pluripotency associated factors Oct4,
Sox2, c-Myc, and Klf4 [104]) have the ability to generate cells corresponding to all three
embryonic germ layers. In contrast, adult stem cells typically reside within postnatal
tissues and demonstrate a comparatively restricted differentiation potential, and act
primarily to repair and replenish adult tissues [105].

1.4.1. Human Embryonic Stem Cells (hESC)
The first human embryonic stem cells (hESC) were derived from blastocysts in
1998 by James Thompson [106]. hESCs can generate mesoderm, endoderm and
ectoderm-derived
differentiation

cell

types

following

spontaneous

embryoid

body-induced

in vitro and teratoma formation in vivo, thus demonstrating their

pluripotent potential [107]. To permit stem cell experimentation, optimal culture
conditions have been developed enabling hESC cell lines to be maintained in vitro
indefinitely without loss of self-renewal or differentiation potential [108-110]. Due to
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their unlimited potential to differentiate into all mature human cells types, hESC
represent an exciting tool for future cell therapy applications.

1.4.2. Human Bone-Marrow derived Multipotent Stromal Cells
Multipotent stromal cells (MSCs) were first derived from the bone marrow of
adult organisms[111]. MSCs, also known as mesenchymal stem cells, are flibroblast-like
cells that grow adherent to plastic and can differentiate into osteoblasts, adipocytes and
chondrocytes [112]. In addition to residing in the bone-marrow compartment [113],
MSCs have been localized to the connective tissues of most organs including skeletal
muscle [114], adipose tissue[115], lung [116], kidney [117], pancreas [118] and the
umbilical cord [119]. It has been demonstrated that MSCs are present in adult organs
throughout the body in close association with pericytes [118]. The perivascular
association of MSCs in adult tissues may be due to their physiological role of localizing
to sites of tissue injury and inducing tissue regeneration and repair. MSCs have been
shown to enhance endogenous repair in various animal models such as lung disease
[120], kidney disease [117], diabetes [121], and graft versus host disease with minimal
signs of long-term engraftment following injection in vivo [122]. Despite low tissue
engraftment, the regenerative effects of MSCs suggests that they regulate tissue repair by
creating a regenerative microenvironment through the secretion of soluble paracrine
factors rather than differentiating to replace cells within damaged tissue [123].
Progenitor subpopulations of MSCs can be purified from the non-hematopoietic
component of the human BM based on high aldehyde-dehydrogenase (ALDH) activity,
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an enzymatic function conserved in endothelial, hematopoietic and mesenchymal
progenitors [121,124]. ALDH high cells have been shown to have higher regenerative
potential than unsorted BM cell populations [121,125,126].

1.5. Cell-Based Therapies for Diabetes Mellitus
1.5.1. Islet Transplantation
Islet-transplantation therapy, commonly known as the Edmonton Protocol, was
developed using islets isolated from cadaveric donor pancreas [127]. These isolated
islets were transplanted into severely type 1 diabetic patients via the hepatic portal vein
and immunosuppressants were administered to protect the newly transplanted cells. All
seven patients transplanted became insulin-independent in the first year of transplantation
[127]. This procedure provided the proof-of-principle that insulin independence can be
achieved using cell-based therapeutics for the treatment of diabetes. However, the severe
shortage of cadaveric donors paired with the requirement of islets from approximately
two to three donors per transplant precludes the widespread use of such therapy.

1.5.2. Differentiation of Embryonic Stem Cells to Islet Cells.
Due to the limited supply of cadaveric islets it has become a priority to generate
alternative sources of insulin-producing cells for transplantation. Pluripotent cells
including hESC and iPSC have the potential to provide an unlimited source for cell-based
regenerative therapies. Given the unlimited potential and proliferative capacity of hESC,
efforts have been made to drive their differentiation towards the β cell fate by attempting
to recapitulate signals present during embryonic development [128-131].
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1.5.2.1 Growth Factor Based Differentiation
Based on growth factor signaling during embryonic development, step-wise
protocols have been developed to produce islet cell populations from pluripotent human
cells, including glucose-responsive β cells [129,131]. During gastrulation, Wnt and TGFβ secretion from the primitive streak is essential for specification of the definitive
endoderm [132,133]. In particular, signaling events triggered by Nodal, a member of
TGF-β family, are critical for definitive endoderm specification [134,135]. The first
reports of definitive endoderm differentiation from hESC [136] used the TGF-β member
Activin A as a substitute for Nodal, since it is readily available and binds to the same
receptors as Nodal [137]. Expression of the definitive endoderm genes CXCR4, SOX17
and FOXA2 were enhanced after 5 day treatment with Activin A. To generate insulinpositive β cells, a landmark study developed a stepwise protocol in which definitive
endoderm cells were subsequently treated with FGF10 for 3 days to generate equivalent
of primitive gut tube, followed by noggin, KAAB-cyclopamine and retinoic acid for 3
days to generate PDX1-positive pancreatic progenitors, and finally cultured in DMEM
supplemented with B27 until 20 days post-definitive endoderm differentiation when Cpeptide levels were detected [131]. Although these studies established that recapitulation
of embryonic growth factor signaling can be used to guide hESC differentiation, the
clinical application of these findings was limited by low efficiency of c-peptide positive
cell differentiation (7%) that were not able to respond to glucose stimulation and the
generation of polyhormonal cells [129].
Building from these initial studies, numerous protocols for β-cell generation have
been developed using various combinations of growth factors, mitogens and small
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molecules that induce pleiotropic effects via activation of multiple, interacting signaling
pathways. Although these protocols induce pancreatic endocrine differentiation from
hESC and accomplish in 25 days what would take 21 weeks in humans, they are limited
as they produce heterogenous populations containing polyhormonal cells, with severe
restriction of cell proliferation from the onset of differentiation [129,131]. Furthermore,
these protocols do not achieve functional maturation of endocrine cells in vitro, requiring
up to 3 months transplantation in vivo to detect glucose-mediated insulin secretion [130].
Although recent protocols have demonstrated the ability to generate monohormonal
insulin-positive cells that are exhibit glucose responsiveness after differentiation in vitro,
they are only 20% as efficient at secreting insulin as adult islet β cells [138]. Thus,
despite recent advances, protocols are still unable to recapitulate appropriate cell
maturation, yielding cells unable to adequately secrete insulin in response to elevated
blood glucose.

1.5.2.2 Transcription Factor Based Differentiation
Previous studies have established the importance of endoderm specification of
hES cells to achieve efficient pancreatic endocrine differentiation [129]. Attempts to
differentiate pancreatic endocrine cells from embryonic stem cells without endoderm
specification led to the development insulin-expressing neural cell precursors [139,140].
Transcription factor-based protocols represent an alternate strategy to generate pancreatic
cell types from hESCs that may lead to more efficient outcomes.
The use of transcription factor-based strategies for pancreatic differentiation has
been recorded extensively in literature. For instance, ectopic expression of Pdx1, Ngn3
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and Mafa to reprogram pancreatic exocrine cells to β cells has been previously
established [141]. Other strategies involve ectopic Ptf1a expression. Ptf1a expression in
Xenopus endoderm induced the formation of endocrine pancreatic tissue but also led in
the generation of exocrine fate [142]. Similarly, ectopic overexpression of Ptf1a in
murine ES cells promoted the generation of exocrine, ductal and endocrine cell fates
[143].

Previous

research

has

demonstrated

that

transcription

factor-mediated

differentiation can generate proliferative, homogeneous, and lineage-restricted definitive
endoderm progenitors (DEPs), that are receptive to signals for further cell-type-specific
maturation. Definitive endoderm specification from hESC was achieved by ectopic
expression of the transcription factor SOX17 in pluripotent stem cells [144]. Building on
the concept of transcription factor-based differentiation, recent studies by the Séguin lab
assayed for the ability of islet-specific transcription factors (PDX1, NGN3, PAX4) to
specify pancreatic endocrine cells from definitive endoderm progenitors (Sattin and
Watts, manuscript in preparation). These studies demonstrated that ectopic expression of
either PAX4 or PDX1 was not sufficient to specify pancreatic cell types from hESC or
DEPs. In contrast, sequential activation of SOX17 and NGN3 in hESC cells resulted in
cells that express hallmarks of pancreatic β cell precursors (PAX4, PDX1, NKX6.1,
NKX2.2, INSULIN). Importantly, NGN3 expression in the absence of SOX17-mediated
DE specification did not promote this phenotype. Similarly, other studies have shown that
ectopic expression of Ngn3 in Xenopus laevis endoderm promotes β and δ cell
development [145]. Collectively, these data provide the proof-of-principle that NGN3
expression can direct definitive endoderm cells towards the pancreas endocrine lineage.
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1.5.3

Islet Regeneration Mediated by Human MSCs
A second strategy to restore islet function is the use of adult stem cells to

stimulate endogenous new islet formation to restore the β-cell mass. Transplantation of
human bone-marrow (BM) derived stem cells has been shown to induce isletregeneration and reverse hyperglycemia in streptozotocin (STZ)-treated non-obsese
diabetic severely compromised immune-deficient (NOD/SCID) mice [146]. Following
MSC transplantation, STZ-treated NOD/SCID mice showed an increase in serum insulin
levels and increased β cell mass [121]. Transplanted MSCs showed engraftment in the
pancreas in vivo but did not exhibit endocrine characteristics, suggesting the rescue of
hyperglycemia in STZ-treated mice was due to the improved function of recipient islets
and endocrine cell proliferation [146]. It was subsequently shown that MSCs induced the
formation of small islet clusters, suggesting the induction of new islet formation in STZtreated mice [147].
Although the precise mechanism underlying endogenous islet regeneration is
unknown, it has been suggested that MSCs release factors and cytokines that induce adult
pancreatic endocrine progenitors to form new islets [121]. This idea is supported by
lineage-tracing experiments that demonstrate that the adult pancreas contains multipotent
progenitors that can give rise to mature endocrine cells [148]. Recent studies have
demonstrated that adult BM-derived MSCs induce islet neogenesis within CK19-positive
pancreatic ductal regions leading to CK19-positive cells found within new islets
[121,147]. Collectively, these studies suggest that MSCs guide endocrine progenitor
populations residing in the ductal regions of adult pancreas to differentiate into mature
islets.
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The islet-regenerative function of MSCs has been shown to vary considerably
from donor to donor, leading to the functional classification of MSC samples as
regenerative or non-regenerative based on their ability to induce islet neogenesis
following in vivo transplantation [126]. Transcriptome analysis of these subset has
established their distinct signatures: regenerative MSCs demonstrate increased expression
of insulin-like growth factor binding protein 5 (IGFBP5), downstream effectors of Wntsignaling such as Wnt1-inducible-signaling pathway protein 1 (WISP1) and secreted
frizzled-related protein 1 (SFRP1), epidermal growth factor receptor (EGFR) ligands
such as amphiregullin (AREG), modulators of the transforming growth factor beta (TGFβ) and also showed increased secretion of pro-angiogenic proteins and show decreased
secretion of anti-inflammatory cytokines than non-regenerative MSCs [121]. These
signaling pathways and their effectors are implicated as potential regulators of MSCinduced islet regeneration [121]. Interestingly, several of these candidate effectors are
essential components of protocols developed to differentiate pluripotent stem cells to
pancreatic endocrine cells, including TGF-β/activin signaling [129,131]. Furthermore,
EGF treatment has been shown to promote islet function and reverse hyperglycemia after
onset of diabetes in NOD mice [149]. Furthermore, EGFR signaling has been shown to
induce β cell mass expansion in mice [150]. The increased expression and secretion of
factors implicated with enhanced islet-function by islet-regenerative MSCs highlights the
importance of paracrine signaling in MSCs-induced islet regeneration.
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1.6. Strategies for Transcription Factor Based Differentiation of hESC
1.6.1. SOX-17 ERT2 System
Previous

studies

in

Séguin

lab

used

constitutive

transcription

factor

overexpression models to study stem cell differentiation, which differ from the inducible
transgene expression strategy undertaken by the current study. Building on SOX17mediated differentiation of hESC to DEPs, it was necessary to refine our strategy to more
accurately recapitulate the developmental pattern of transcription factor activation by
generating inducible cell lines that allow to down-regulation of SOX17 following DEP
specification.

hESC lines with inducible SOX17 expression (CA2-pCAGG-SOX17-

ERT2) were previously generated in the Séguin lab. SOX17-ERT2 is a fusion protein of
SOX17 and a mutant form of human estrogen receptor (ERT2) that does not bind to its
endogenous ligand (17β-estradiol) at physiological concentrations but will bind to 4hydroxytamoxifen (4OHT) at low concentrations,promoting ERT2 nuclear localization..
In these cells, SOX17-ERT2 is constitutively expressed under the control of strong
cytomegalovirus (CMV) early enhancer/chicken β actin promoter (CAGG), and upon
treatment of cells with 4OHT it becomes localized to the nucleus allowing SOX17 to
function as a transcription factor.

1.6.2. NGN3 piggyBac System
In order to control differentiation downstream of SOX17 activation, we made use
of a second gene expression system that would confer inducible expression of NGN3. We
employed the transposon-based Tet-inducible piggyBac system [151] for NGN3 (PBNGN3) which is comprised of three separate vectors: 1) TetO-NGN3-IRES-βGEO, 2)
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pCAGG-rtTA, and 3) CMV-transposase element. While the first two vectors become
stably integrated into the genome, the vector expressing the transposase element is
transiently expressed and enables the incorporation of the other two vectors. The PBNGN3 system utilizes the Tet-on system of transgene induction in which reverse
tetracycline transcriptional activator (rtTA) is constitutively expressed and upon binding
to doxycycline binds to the operator region upstream of NGN3-IRES-βGEO. Thus,
expression of NGN3 is induced following treatment of cells with doxycycline.

1.6.3. Strategies for Enhancing Maturation of Endocrine Precursors Cells
Our group has previously shown that human MSC induce endogenous islet
regeneration when injected into immune deficient mice following streptozotocinmediated β-cell destruction [121]. Although the precise mechanisms responsible for the
induction of islet regeneration remain a topic under intense investigation, it has been
established that MSCs promote islet regeneration in vivo with minimal long-term tissue
engraftment, suggesting the role of MSC-secreted secreted paracrine factors in promoting
islet regeneration from resident endocrine progenitors [121]. We therefore extrapolated
from these findings and developed in vitro strategies using MSC-conditioned media
(MSC-CM) to generate a microenvironment to promote pancreatic endocrine maturation
of hESC-derived precursor cells.

1.7.

Rationale
Definitive endoderm specification from hESC has been achieved by ectopic

expression of the transcription factor SOX17 [144]. Furthermore, preliminary studies
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show that sequential expression of SOX17 and NGN3 in hESCs (using a genetic strategy
that conferred constitutive transgene expression) results in cells that express hallmarks of
pancreatic β-cell precursors. Importantly, pancreatic differentiation following ectopic
NGN3

expression

was

dependent

on

SOX17-mediated

definitive

endoderm

differentiation. We therefore sought to use the SOX17-ERT2 and PB-NGN3 transgenic
cell lines to develop a protocol to create pancreatic endocrine precursor populations from
hESC. Previous studies demonstrated that the generation of functional β cells from
hESCs is enhanced after transplantation in vivo [130], demonstrating the importance of
the cell microenvironment on differentiation, development and maturation. We predict
that following NGN3-mediated endocrine specification of hESC, maturation will be
required to promote the transition from endocrine precursors to functional and mature
endocrine cells in vitro. Because the microenvironmental factors that control the final
stages of endocrine cell maturation are largely unknown, we propose that soluble factors
secreted by islet-regenerative human BM-derived MSCs will accelerate endocrine cell
maturation.

1.8.

Hypothesis

Hypothesis I: NGN3-mediated differentiation of SOX17-definitive endoderm will
produce pancreatic endocrine precursor cells.
Hypothesis II: SOX17/NGN3 differentiated cells will be receptive to maturation signals
secreted by islet-regenerative MSCs facilitating the production of mature pancreatic
endocrine cell.
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1.9.

Objectives

Objective I: Develop a transcription factor-based protocol to differentiate hESC to
differentiate pancreatic endocrine-cell precursors via sequential activation of SOX17
(definitive endoderm specification) and NGN3 (endocrine precursor specification).
Objective II: Evaluate the effects of islet-regenerative human MSC-conditioned media in
directing the maturation of endocrine precursors in vitro.
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CHAPTER 2:
Materials and Methods
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2.1.

Generation of NGN3 expression constructs
The open reading frame (ORF) corresponding to the human NGN3 gene was

amplified by PCR using primers designed to incorporate the endogenous Kozac sequence
and to add attB recombination sites to permit Gateway® cloning (Life Technologies). An
entry clone was generated by a recombination reaction between the pDONRTM221 vector
(Life Technologies) and the attB-NGN3 PCR product. The NGN3 ORF was introduced
into the piggyBac (PB) transposon system, which allows for efficient transgene delivery
in hESC [151] by Gateway® cloning. The resultant Tet-inducible piggyBac system [151]
for NGN3 expression (PB-NGN3) was comprised of three separate vectors: 1) TetONGN3-IRES-βGEO, 2) CAGG-rtTA, and 3) CMV-transposase element. The first two
vectors become stably integrated into the genome because the vector expressing the
transposase element is transiently expressed and enables the incorporation of the other
two vectors.

The PB-NGN3 transgene utilizes the Tet-on system in which reverse

tetracycline transcriptional activator (rtTA) is constitutively expressed and upon binding
to doxycycline is activated and binds to the operator region upstream of NGN3-IRESβGEO. Following cloning, the PB-NGN3-IRES-βGEO construct was verified by
sequencing (Figure 2.1).

2.2.

Generation of transgenic SOX17-ERT2; PB-NGN3 inducible cell lines
hESC lines with inducible SOX17 activity (CA2-SOX17-ERT2) were previously

generated by the Séguin lab. In order to generate a transgenic cell line with inducible
expression of both SOX17 and NGN3, the PB-NGN3-IRES-βGEO (PB-NGN3) construct
was introduced along with the PB-rtTA and PB-transposase constructs into CA2-SOX17-
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Figure 2.1. Alignment of the human NGN3 coding sequence with that of the PB-NGN3
transgene. Missing base pairs (N) in sequencing results were verified by aligning the
unknowns to their corresponding chromatograph.
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ERT2 cells by electroporation (170 V, 1050 µF). rtTA integration was selected for by
blasticidin resistance (5µg/ml) and clonal cell populations were expanded from single
colonies. PB-NGN3 plasmid integration was selected for by treating replica well with
doxycycline (24h; 0.5 µg/mL) to induce PB-Tet transcription which confers neomycin
resistance through the expression of beta-galactosidase neomycin fusion protein (βGEO),
and transgene-positive cells were selected by G418 resistance (50 µg/mL).
Undifferentiated cells of the corresponding clonal populations in replica wells were then
expanded and cryopreserved.

2.3.

Cell culture
All hESC, including parental CA2, SOX17-ERT2, and SOX17-ERT2; PB-NGN3

were maintained using established protocols [106]. Cells were grown on γ-irradiated
mouse embryonic fibroblast feeders (MEFs; SickKids ESC Facility) in KnockOut
Dulbecco’s Modified Eagle Medium (KO-DMEM; Life Technologies) supplemented
with 15% KnockOut serum replacement (Life Technologies), 2 mM GlutaMAX, 0.1 mM
nonessential amino acids (NEAA), 0.5 mM 2-mercaptoethanol, and 10 ng/mL FGF2 (all
from Life Technologies). Transgenic cell populations were maintained in media
supplemented with Puromycin to select for the SOX17-ERT2 transgene (Bioshop, 0.8
µg/mL) or G418 (50 µg/ml) to select for the PB-NGN3 transgene. For activation of
SOX17-ERT2, 4-hydrotamoxifen (4OHT) was administered (0.2 µM). For activation of
PB-NGN3, doxycycline (DOX) was administered (0.5 µg/mL). When cultures had
attained 75% confluence, cells were passaged by enzymatic dissociation (0.05% TrypsinEDTA; Life Technologies) at split ratio of 1:12 (every 4-6 days). All protocols were
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reviewed and approved by the CIHR Stem Cell Oversight Committee (SCOC) as well as
the Research Ethics Board (REB) at the University of Western Ontario.
Human BM-derived MSCs were cultured in serum-free MSC media
(STEMPRO® MSC SFM; Life Technologies), supplemented with STEMPRO® MSC
SFM Supplement CTSTM (Life Technologies) and 2mM L-glutamine. When cultures
attained 75% confluence, cells were passaged by enzymatic dissociation (0.5% TrypsinEDTA; Life Technologies) and seeded at a density of 10000 cells/cm2.
Human ductal epithelial carcinoma cells (PANC-1) [152] were maintained in
DMEM + 10% Fetal Bovine Serum (FBS). PANC-1 cells were passaged every 3 days (at
approximately 75% confluence) by enzymatic dissociation (0.5% Trypsin-EDTA; Life
Technologies).

2.4.

Generation of MSC Conditioned Media (CM)
Human BM-derived MSC, previously screened for islet regenerative capacity

after transplantation in vivo [126] were thawed from vials cryopreserved at passage 3 and
maintained in culture to passage 6 in serum-free MSC media. At each passage,
conditioned media was harvested (10 mL/T75 flask) following approximately 48 h of
culture, and immediately stored at -20°C. For hESC-derived cultures, equal volumes of
CM from MSC at passages 3-6 were combined, and supplemented with an additional
30% fresh serum free MSC media (STEMPRO® MSC SFM; Life Technologies).
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2.5. Quantification of PANC-1 cell proliferation
Human ductal epithelial carcinoma cells (PANC-1) were plated at a density of
8,820 cells/cm2 (in 96 well plates; 3,000 cells/well) and cultured in DMEM + 10% FBS
for 4 h to permit cell adhesion. Media was then replaced with MSC-CM, DMEM + 10%
FBS (positive control), unconditioned serum free MSC media + supplement, or
unconditioned serum free MSC media without supplement (negative control). After 72 h
cell proliferation was quantified using the CyQUANT® cell proliferation assay kit
(Invitrogen) according to the manufacturer’s instructions.

2.6. Gene expression analysis
Total RNA was isolated from cell cultures at specified time points using TRIzol®
Reagent (Life Technologies) according to the manufacturer’s instructions and quantified
by spectrophotometry on a Nanodrop 2000 (Thermo Scientific). cDNA was reverse
transcribed from 0.5 µg of input RNA with the iScript cDNA synthesis kit (Bio-Rad
Laboratories). mRNA expression was assessed by quantitative real-time PCR using the
BioRad CFX384. PCR reactions were performed in triplicate using 2.5 ng of cDNA per
reaction and 312 nM forward and reverse primers (sequences provided in Table 2.1) with
2X SsoFast EvaGreen Supermix (Bio-Rad Laboratories) for 40 cycles of amplification
(95°C 10 sec melt; 60°C 30 sec annealing/elongation). For phenotypic analysis, gene
specific primers were designed to attain efficiency values between 90-110% and melt
curve analysis was used to confirm primer specificity. mRNA expression was determined
by relative quantification (ΔΔCt) corrected for input using the housekeeper gene Betaglucuronidase (GUSB) and normalized relative to undifferentiated hESC.
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Table 2.1. Primer sequences.
Gene
Sequence (5’ to 3’)
AMY
Forward AATACACAACAACAAGGACGGACATC
Reverse TCCAAATCCCTTCGGAGCTAAA
βGEO
Forward CCTGCTGATGAAGCAGAACA
Reverse TTGGCTTCATCCACCACATA
CCKBR Forward TTCACCAGAACGGGCGTTG
Reverse TGGAAGTTGCACGTAGCAGC
CER1
Forward ACAGTGCCCTTCAGCCAGACT
Reverse ACAACTACTTTTTCACAGCCTTCGT
CK19
Forward TGAGTGACATGCGAAGCCAA
Reverse TCAATTCTTCAGTCCGGCTGGT
CXCR4 Forward CACCGCATCTGGAGAACCA
Reverse GCCCATTTCCTCGGTGTAGTT
DLX5
Forward CGCCTCGCTGGGATTG
Reverse CTTGATCTTGGATCTTTTGTTCTGAA
GCG
Forward AAGCATTTACTTTGTGGCTGGATT
Reverse TGATCTGGATTTCTCCTCTGTGTCT
GUSB
Forward ACGCAGAAAATATGTGGTTGGA
Reverse GCACTCTCGTCGGTGACTGTT
INS
Forward AAGAGGCCATCAAGCAGATCA
Reverse CAGGAGGCGCATCCACA
NANOG Forward TGATTTGTGGGCCTGAAGAAA
Reverse GAGGCATCTCAGCAGAAGACA
NGN3Forward GGGGACAAGTTTGTACAAAAAAGCAGGCTGCATGACGC
att
CTCAACCCTCGGG
(cloning)
Reverse GGGGACCACTTTGTACAAGAAAGCTGGGTTTCACAGAA
AATCTGAGAAAG
NKX2.2 Forward CGGGCCGAGAAAGGTATGG
Reverse CTTTGAGCGCGTGACATGG
NKX2.5 Forward CCCAGCCAAGGACCCTAGA
Reverse GCGTTGTCCGCCTCTGTCT
NKX6.1 Forward CACACGAGACCCACTTTTTCC
Reverse CCCAACGAATAGGCCAAACG
OCT4
Forward TGGGCTCGAGAAGGATGTG
Reverse GCATAGTCGCTGCTTGATCG
PAX4
Forward GGGTCTGGTTTTCCAACAGAAG
Reverse TCAGCCCCTGGGAAGCA
PAX6
Forward CCAGAAAGGATGCCTCATAAAGG
Reverse TCTGCGCGCCCCTAGTTA
PDX1
Forward AAGTCTACCAAAGCTCACGCG
Reverse GTAGGCGCCGCCTGC
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PECAM
SOX3
SST

Forward
Reverse
Forward
Reverse
Forward
Reverse

GGAAAAGGCCCCAATACACTT
TAAAACGCGGTCCTGTTCTT
CCAGTCGTGTCGCGTCTGT
GCACACCTGGCTATAAATTAACATTG
CCCCAGACTCCGTCAGTTTC
TCCGTCTGGTTGGGTTCAG
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PB-NGN3 transgene expression was quantified in clonal hESC populations
(SOX17ERT2; PB-NGN3) by absolute quantifications. Primers were designed to amplify
a 112 bp sequence specific to the βGEO transgene (Table 2.1). mRNA concentrations
values of SOX17-ERT2; PB-NGN3 clonal cell lines were quantified using a 6 point
standard curve generated from the PB-NGN3 construct (start = 33 ng, 1:10 serial
dilutions).

2.7.

Immunostaining
Cells were fixed in 4% (w/vol) paraformaldehyde (PFA) for 10 min at room

temperature, rinsed twice in phosphate buffered saline (PBS), and blocked for 1 h in
PBST (PBS + 0.1% Triton X-100 (Sigma)) + 5% species specific serum (blocking
buffer). Primary antibodies diluted in blocking buffer were incubated overnight at 4⁰C
followed by secondary antibody incubation for 1 h at room temperature. For nuclear
staining, 1:1000 Hoechst 33258 (Sigma Aldrich) was added in the last 10 min of the
secondary antibody incubation period. The following antibodies and dilutions were used:
anti-NGN3 1:100 (Santa Cruz, SC-13793), anti-ISL1 1:50 (University of Iowa
Hybridoma Bank, clone 39.4D5), anti-PAX6 1:100 (University of Iowa Hybridoma
Bank, clone PAX6), anti-INS 1:350 (Sigma-Aldrich, Inc., I2018), anti-SST 1:200 (Beta
Cell Biology Consortium, AB1985), Alexa Fluor 488 donkey anti-goat IgG 1:400
(Molecular Probes), Alexa Fluor 488 goat anti-mouse IgG 1:400 (Molecular Probes) and
Texas Red® horse anti-mouse (1:200).
Imaging was performed using a Leica DMI6000B Inverted Microscope equipped
with a Leica DFC360 FX High Resolution Camera. Images were analyzed in Leica
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Application Suite Advanced Fluorescence (LAS AF) software. The mouse βTC6 cell line
(β cells expressing T-antigen of simian virus 40 (SV40) [153]) was used as a positive
control (Appendix 1), and cells incubated without primary antibody were used as
negative control (Appendix 2) to assess the efficiency of staining. Although βTC6 cells
are primarily a β insulinoma cell line, they are also known to contain cells that express
small amounts of somatostatin protein [153], and therefore served as an appropriate
positive control for all antibodies used in this study. For all immunostaining, the exposure
time for each fluorescence channel was optimized using βTC6 cells, and the exposure
time was standardized accordingly. Image acquisition parameters for each antibody
including exposure and gain settings were kept constant to facilitate direct comparison
between images.

2.8.

β-galactosidase staining
Cells were fixed in 0.25% (vol/vol) glutaraldehyde for 10 min at room

temperature and rinsed twice in PBS. Cells were incubated with X-gal solution (0.2%
(w/vol) X-gal + 2mM MgCl2 + 5mM K4Fe(CN)6 + 5mM K3Fe(CN)6) overnight at room
temperature. Imaging was performed using Leica DMI6000B Inverted Microscope
equipped with a Leica DFC295 Colour Camera. Images were analyzed in Leica
Application Suite Advanced Fluorescence (LAS AF) software.

2.9.

Statistical analysis
Statistical analyses were performed using GraphPad Prism version 6. All data

were expressed as mean ± SEM, and appropriate statistical tests were chosen based on

42
the number of groups and the number of independent variables (see figure legends for
detail). p<0.05 was considered significant.
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CHAPTER 3:
Results
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3.1.

Characterization of CA2 SOX17ERT2; PB-NGN3 clonal cell lines
To generate hESC lines with inducible expression of both SOX17 and NGN3, the

piggyBac transposon system was used to introduce doxycycline-inducible NGN3
expression to a cell line carrying the SOX17-ERT2 transgene (Figure 3.1A). G418resistant clonal cell populations were isolated and expanded (12 clones total). Expression
of the PB-NGN3 construct was confirmed in each clonal cell line by quantifying mRNA
expression of the βGEO element (transcribed along with NGN3 from the tetO promoter)
following 48 h treatment of cells with DOX (0.5 µg/ml) (Figure 3.1B). In all SOX17ERT2; PB-NGN3 clonal cell lines, transgene expression was exclusively detected
following DOX treatment, confirming the functionality of the piggyBac system. Based on
absolute qRT-PCR quantification of the PB-NGN3-βGEO transcript, clones were
designated as either high or low PB-NGN3 (Figure 3.1B). All subsequent experiments
were conducted using one representative SOX17-ERT2/PB-NGN3 low cell line (clone F)
and one representative SOX17-ERT2; PB-NGN3 high cell line (clone G).
In order to verify protein induction, X-gal staining was performed to detect βgalactosidase activity (Figure 3.1C). β-galactosidase activity was detected in both
SOX17-ERT2; PB-NGN3LOW and SOX17-ERT2/PB-NGN3HIGH cells following DOX
treatment. Furthermore, NGN3 protein induction in representative low and high clonal
cell lines was verified by immunocytochemistry (Figure 3.2A and B). Like βgalactosidase activity, NGN3 protein induction was only detected in both clonal cell lines
following DOX treatment.
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Figure 3.1. Characterization of clonal hESC lines with inducible NGN3 expression.
A) Schematic illustration of the SOX17-ERT2 and piggyBac (PB)-NGN3-βGEO
transgene expression systems. βGEO-specific primer annealing sites used to quantify PB
transgene expression are indicated by blue arrows. B) Quantification of PB transgene
expression by qRT-PCR in SOX17-ERT2; PB-NGN3 clonal cell lines with or without
DOX treatment (48 h). C) X-gal staining to detect β-galactosidase activity in SOX17ERT2; PB-NGN3 low and high cell lines with or without DOX treatment (72 h). Scale bar
equals 100µm. White arrowheads indicate cell colonies.
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Figure 3.2. Immunolocalization of NGN3. Immunocytochemistry of NGN3 in A)
SOX17-ERT2; PB-NGN3 low and B) SOX17-ERT2; PB-NGN3 high clonal cell lines with
or without DOX treatment (72 h). Scale bar equals 100µm.
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3.2.

Differentiation of pluripotent hESCs to definitive endoderm progenitors

(DEP)
Based on our preliminary data and previous description of stepwise pancreatic
differentiation [136], SOX17-ERT2; PB-NGN3LOW/HIGH cells were subjected to an initial 5
days of SOX17 activation to initiate DE differentiation. To confirm that this period was
sufficient for DEP specification, SOX17-ERT2; PB-NGN3LOW and SOX17-ERT2; PBNGN3HIGH cells were harvested following 5 days SOX17 activation (4OHT treatment; in
the absence of DOX-induction of NGN3) and the expression of DE markers was
assessed. In both cell lines, 4OHT-mediated SOX17 activation significantly induced the
expression of known DE markers CXCR4 and DLX5 mRNA when compared to
untreated cells (Figure 3.3). Changes in CER1 expression in both cell lines were not
significantly different from untreated cells after 5 days of 4OHT treatment (Figure 3.3).
Collectively, these results suggest the induction of DE phenotype.

3.3.

NGN3 expression directs SOX17-DEPs to a pancreatic endocrine fate
Having established our ability to drive SOX17-mediated DE differentiation, we

next assessed the effect of ectopic NGN3 expression in DE progenitors. NGN3
expression was induced by DOX treatment in SOX17-ERT2; PB-NGN3LOW and SOX17ERT2; PB-NGN3HIGH clones subsequent to 5 days of SOX17 activation, and changes in
cell phenotype were assessed over 12 days. We verified that the expression of PB-NGN3
transgene was maintained during the differentiation by quantifying mRNA levels of the
βGEO element after 12 days of DOX treatment (0.5 µg/ml) (Figure 3.4A).
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Figure 3.3. Characterization of SOX17-induced definitive endoderm differentiation
in SOX17-ERT2;PB-NGN3 cell lines. Real-time PCR analysis of definitive endoderm
markers following 5 days of SOX17 activation in SOX17-ERT2; PB-NGN3LOW and
SOX17-ERT2; PB-NGN3HIGH cells. Gene expression is corrected for input based on
expression of GUSB and expressed relative to undifferentiated hESC. Data are presented
as the mean ± SEM (n = 4). Statistical analysis was performed using one-tailed Student’s
t-test; * indicates significant difference compared to control (untreated) cells (p<0.05).
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Figure 3.4. SOX17-ERT2; PB-NGN3LOW and SOX17-ERT2; PB-NGN3HIGH clones
show loss of pluripotency-associated factors following NGN3 induction. A)
Quantification of PB transgene expression by qRT-PCR in SOX17-ERT2; PB-NGN3
clonal cell lines after 12 days of DOX treatment. B) Representative images
demonstrating the morphology of SOX17-ERT2; PB-NGN3LOW and SOX17-ERT2; PBNGN3HIGH cell lines following 3, 6, 9 or 12 days of NGN3 induction post SOX17mediated DE induction (indicated as Day 0). As cells remained proliferative following
transgene induction, cultures were passaged following 5 days of SOX17 induction
(indicated as Day 0) and at day 6 (indicated by blue arrows). White arrowheads indicate
individual cell colonies. Scale bar equals 100µm. C) Real-time PCR analysis of
pluripotency markers OCT4 and NANOG over 12 days of NGN3 induction. Gene
expression is corrected for input based on expression of GUSB and expressed relative to
Day 0 of NGN3 induction (DE progenitor cells). Data are presented as the mean ± SEM
(n=3). For each gene, statistical analysis was performed using One-way ANOVA with
Tukey’s multiple comparisons post-hoc test. * indicates significant difference (P<0.05)
from expression at day 0 for each gene; X indicates significant difference from
expression at day 3 for each gene; Δ indicates significant difference from expression at
day 6 for each gene.
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After 3 days of NGN3 induction, both SOX17-ERT2; PB-NGN3 LOW and SOX17ERT2; PB-NGN3HIGH cells retained a high nucleus to cytoplasm ratio and grew within
tightly packed colonies, features characteristic of both hESC and DE progenitor cells.
However, following 9 days of NGN3 induction, SOX17-ERT2; PB-NGN3HIGH cells
appeared larger in size, and did not grow within densely packed cell colonies when
compared to the starting population of DE progenitors (Day 0) (Figure 3.4B). In contrast,
SOX17-ERT2; PB-NGN3LOW cells did not show overt morphological changes over the 12
days of NGN3 induction (Figure 3.4B).
To assess the effect of NGN3 induction on the expression of pluripotencyassociated transcription factors, expression of OCT4 and NANOG were assessed by qRTPCR at multiple time points over 12 days of NGN3 induction. Both SOX17-ERT2; PBNGN3 clonal cell lines showed a significant reduction in both OCT4 and NANOG
mRNA expression within 3 days of NGN3 induction. However, SOX17-ERT2; PBNGN3LOW cells demonstrated a progressive reduction in pluripotency-associated gene
expression over the 12 days of NGN3 induction while SOX17-ERT2; PB-NGN3HIGH cells
showed a sharp reduction at day 3 with no subsequent change in gene expression levels
from day 3 to day 12 (Figure 3.4C). Taken together, these data suggest that both low and
high levels of NGN3 expression in SOX17-DEPs result in cell differentiation and loss of
pluripotency-associated markers.
To determine whether NGN3 activation stimulated pancreatic endocrine cell
differentiation, we assessed the expression of transcription factors associated with early
pancreatic endocrine differentiation (PAX4, PAX6 NKX6.1 and NKX2.2), β cell
phenotype (PDX1), δ cell phenotype (CCKBR), β and δ cell phenotype (ISL1), and ductal
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epithelial cell phenotype (CK19). In addition, mRNA transcript levels for pancreatic
endocrine hormones insulin (INS), glucagon (GCG), somatostatin (SST) and the exocrine
pancreatic enzyme amylase (AMY) were assessed using qRT-PCR. SOX17-ERT2; PBNGN3LOW and SOX17-ERT2; PB-NGN3HIGH cells showed divergent patterns in the
expression of early pancreatic endocrine markers (Figure 3.5A). SOX17-ERT2; PBNGN3HIGH cells showed a significant induction of PAX4 expression, a direct target of
NGN3 [154] crucial for β and δ cell differentiation [91], after 3 days of DOX treatment
with expression returning to baseline by day 6 (Figure 3.5A). SOX17-ERT2; PBNGN3HIGH cells also showed early induction of PAX6 expression, a transcriptional factor
critical for the development of all pancreatic endocrine subtypes and also expressed in all
mature pancreatic endocrine cells [89], after 6 days of NGN3 induction when compared
to undifferentiated controls (Figure 3.5A). In contrast, SOX17-ERT2; PB-NGN3LOW cells
did not show significant induction of these genes (Figure 3.5A). NKX6.1 expression, a
transcription factor implicated in early β and δ cell progenitor fates [96] and with mature
β cell function [89,97], was significantly upregulated in both clones at day 12 of NGN3
induction (Figure 3.5A). Interestingly, the expression of NKX2.2, a TF important for
terminal differentiation of β cells and suppression of the δ cell phenotype [99], was not
significantly induced by ectopic NGN3 expression in either clone (Figure 3.5A). These
data suggest that level of NGN3 expression in SOX17-DEPs is important in the induction
of early pancreatic endocrine genes.
The expression of markers of mature endocrine cell types also varied between
NGN3 high and low-expressing cell lines. SOX17-ERT2; PB-NGN3HIGH but not SOX17ERT2; PB-NGN3LOW cells showed increased expression of the β cell marker PDX1 [155]
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Figure 3.5. NGN3 induction in SOX17 DEPs promotes expression of pancreatic
endocrine markers. Real-time PCR analysis of genes associated with pancreatic
endocrine development and function over 12 days of NGN3 induction post SOX17mediated DE differentiation (indicated as day 0). A) Markers of early pancreatic
endocrine differentiation, B) markers of β cell and/or δ cell fates, C) marker of pancreatic
ductal epithelia, and D) pancreatic hormones (INS, GCG, SST) and exocrine marker
(AMY). Gene expression is corrected for input based on expression of GUSB and
expressed relative to undifferentiated hESC. Data are presented as mean ± SEM (n=3).
Statistical analysis was performed using two-way ANOVA with Tukey’s multiple
comparisons post-hoc test. * indicates significant difference (P<0.05) from day 0 (SOX17
definitive endoderm cells) for each cell line as indicated by colour.

55
after 12 days of NGN3 induction (Figure 3.5B). However, INS gene expression was not
significantly upregulated in either cell population during the 12 day period of NGN3
induction (Figure 3.5B).

In contrast, SOX17-ERT2; PB-NGN3LOW cells showed a

significant induction of the δ cell markers SST and CCKBR [40] (Figure 3.5B & D). The
expression of neither the α cell marker glucagon (GCG) nor the exocrine pancreas marker
amylase (AMY) [156] were induced by NGN3 induction in either cell line (Figure 3.5D).
Interestingly, ISL1, a TF that co-regulates both SST and INS gene expression [102,157],
was also not significantly induced in either cell line (Figure 3.5B). Unexpectedly, we
noted the induction of CK19 expression, a marker of pancreatic duct cells [158],
following 6 days of NGN3 induction in SOX17-ERT2; PB-NGN3LOW cells but not in
SOX17-ERT2; PB-NGN3HIGH cells (Figure 3.5C). Collectively, these data suggest that
the level NGN3 expression directs endocrine pancreatic differentiation such that high
NGN3 expression promoted β cell-like characteristics, while lower NGN3 expression
promoted a δ cell-like expression profile with some ductal cell characteristics.
The induction of PAX6 and ISL1 protein were subsequently assessed by
immunocytochemistry in SOX17-ERT2; PB-NGN3LOW (Figure 3.6 and 3.7) and SOX17ERT2; PB-NGN3HIGH (Figure 3.8 and 3.9) cell lines at multiple time points during 12
days of NGN3 induction following SOX17-mediated DE specification. Interestingly, in
SOX17-ERT2; PB-NGN3LOW cells small clusters of PAX6-positive (Figure 3.6) and
ISL1-positive (Figure 3.7) cells were detected after 9 and 12 days of NGN3 induction
even though changes in gene expression were not significant (Figure 3.5). We likewise
observed clusters of SOX17-ERT2; PB-NGN3HIGH cells showing convincing nuclear
localization of PAX6 (Figure 3.8) and ISL1 (Figure 3.9) after 9 and 12 of NGN3
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Figure 3.6. NGN3 induction in SOX17-ERT2; PB-NGN3LOW cells induces areas of
PAX6 positive cells. Representative images demonstrating immunocytochemistry of the
pancreatic endocrine development transcription factor PAX6 after A) 6, B) 9 and C) 12
days of NGN3 induction post SOX17-mediated DE differentiation. Areas with positive
immunoreactivity were magnified (indicated by boxes). Arrows indicate areas positive
for nuclear localization of PAX6. Scale bar equals 100µm. n = 3.
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Figure 3.7. NGN3 induction in SOX17-ERT2; PB-NGN3LOW cells induces areas of
ISL1 positive cells. Representative images demonstrating immunocytochemistry of the
pancreatic endocrine development transcription factor ISL1 after A) 6, B) 9 and C) 12
days of NGN3 induction post SOX17-mediated DE differentiation. Areas with positive
immunoreactivity were magnified (indicated by boxes). Arrows indicate representative
areas positive for nuclear localization of ISL1. Scale bar equals 100µm. n = 3.
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Figure 3.8. NGN3 induction in SOX17-ERT2; PB-NGN3HIGH induces areas of PAX6
positive cells. Representative images demonstrating immunocytochemistry of the
pancreatic endocrine development transcription factor PAX6 after A) 6, B) 9 and C) 12
days of NGN3 induction post SOX17-mediated DE differentiation. Areas with positive
immunoreactivity were magnified (indicated by boxes). Arrows indicate representative
areas positive for nuclear localization of PAX6. Scale bar equals 100µm. n = 3.
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Figure 3.9. NGN3 induction in SOX17-ERT2; PB-NGN3HIGH cells induces areas of
ISL1 positive cells. Representative images demonstrating immunocytochemistry of the
pancreatic endocrine development transcription factor ISL1 after A) 6, B) 9 and C) 12
days of NGN3 induction post SOX17-mediated DE differentiation. Areas with positive
immunoreactivity were magnified (indicated by boxes). Arrows indicate representative
areas positive for nuclear localization of ISL1. Scale bar equals 100µm. n = 3.
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induction. However, we observed heterogeneity in both clonal cell lines, with a
significant number ISL1 and PAX6-negative cells observed at both day 9 and 12 of
NGN3 induction. Although we did not observe a homogeneous population of
differentiated cells, we noted that the proportion of positive cells was greater in later
stages of NGN3 induction (days 9 and 12) than at earlier stages (day 6). Considering that
PAX6 and ISL1 are crucial for the development and specification of all islet cells
[95,159], these data collectively suggest that expression of NGN3 in SOX17-DEPs
directs a pancreatic endocrine phenotype.
We also performed immunocytochemistry for INS (Figure 3.10) and SST
(Figure 3.11 and 3.12) in both SOX17-ERT2; PB-NGN3 cell lines after 12 days of
NGN3 expression. We did not detect INS protein in either clone during the course of
NGN3 induction. These data support our findings showing INS mRNA expression was
not significantly induced in either SOX17-ERT2; PB-NGN3LOW or SOX17-ERT2; PBNGN3HIGH cells during the course of NGN3 induction (Figure 3.5). Also, we did not
detect convincing cytoplasmic immunofluorescence for SST in SOX17-ERT2; PBNGN3LOW cells over 12 days of NGN3 induction (Figure 3.11), even though we detected
a significant induction of SST mRNA by day 12 of NGN3 expression (Figure 3.5).
Similarly, we did not detect convincing cytoplasmic staining for SST in SOX17-ERT2;
PB-NGN3HIGH cells over 12 days of NGN3 induction (Figure 3.12). The fluorescence
detected in both SOX17-ERT2; PB-NGN3 clones is not characteristic of positive
cytoplasmic hormone staining as detected by SST immunocytochemistry in βTC6 cells
(Figure 3.11A).
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Figure 3.10. SOX17-ERT2; PB-NGN3 cells do not express insulin protein after 12
days of NGN3 induction. Immunocytochemistry of insulin in: A) βTC6 cells as positive
control, and B) SOX17-ERT2; PB-NGN3LOW and C) SOX17-ERT2; PB-NGN3HIGH cells
after 9 and 12 days of NGN3 induction. Scale bar equals 100 µm. n = 4.
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Figure 3.11. SOX17-ERT2; PB-NGN3LOW cells do not express SST protein after 12
days of NGN3 induction. Representative images demonstrating immunocytochemical
detection of SST in: A) βTC6 cells as positive control, and SOX17-ERT2; PB-NGN3LOW
cells after B) 9 and C) 12 days of NGN3 induction. Areas with positive immunoreactivity
were magnified (indicated by boxes). Scale bar equals 100 µm. n = 3.
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Figure 3.12. SOX17-ERT2; PB-NGN3HIGH cells express do not express SST protein
after 12 days of NGN3 induction. Representative images demonstrating
immunocytochemical detection of SST in: SOX17-ERT2; PB-NGN3HIGH cells after A) 9
and B) 12 days of NGN3 induction. Areas with apparent immunoreactivity were
magnified (indicated by boxes). Scale bar equals 100 µm. n = 3.
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We also attempted immunocytochemistry for NKX2.2 and NKX6.1 but were unable to
obtain convincing images due to high levels of non-specific background staining.

3.4.

Development of in vitro strategy to assess the effects of MSC-secreted factors

on the differentiation of SOX17-ERT2; PB-NGN3 cells
In order to determine the effects of MSC-conditioned media on our SOX17-ERT2;
PB-NGN3 endocrine precursor populations, it was necessary to first assess whether the
serum-free MSC media would support hESC growth without inducing spontaneous
differentiation. Therefore, we cultured undifferentiated SOX17-ERT2 hESCs (no 4OHT
treatment) in serum-free MSC media for 5 days and compared them to cells maintained
for the same period in standard culture conditions (hESC media). Cells maintained under
either culture condition demonstrated morphological characteristics associated with
pluripotent hESC, such as high nuclear to cytoplasmic ratio and dense colonies with
sharp contrasting borders (Figure 3.13A). No morphological signs of spontaneous
differentiation were observed for either condition. We next assessed the expression of
pluripoency markers (OCT4, NANOG), a neuroectodermal marker (SOX3), early
mesoderm marker (NKX2.5), and endothelial marker (PECAM) in undifferentiated
SOX17-ERT2 cells and SOX17-ERT2 cells treated with 4OHT over 5 days culture in
hESC media or MSC media (Figure 3.13B). Under both conditions, cells maintained
expression of OCT4 and NANOG mRNA, as expected for both undifferentiated hESC
and DEPs. Furthermore, no induction of PECAM or NKX2.5 was detected under either
condition, suggesting the absence of mesodermal differentiation (Figure 3.13B). Culture
of undifferentiated SOX17-ERT2 cells or SOX17-DEPs in MSC
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Figure 3.13. Culture of hESC and SOX17-DEPs in serum-free MSC media does not
promote spontaneous differentiation. A) Representative images of undifferentiated
SOX17-ERT2 cells cultured in either hESC media or MSC serum-free media. Scale bar
equals 100µm; arrowheads indicate individual cell colonies. B) Real time-PCR analysis
of pluripotent markers (OCT4, NANOG), ectodermal (SOX3) and mesodermal markers
(NKX2.5, PECAM) expression in SOX17-ERT2 cells with or without 4OHT treatment
(0.2 µM) grown in either hESC media or MSC serum-free media for 5 days. Gene
expression is corrected for input based on expression of GUSB and expressed relative to
undifferentiated hESC. Data are presented as the mean ± SEM (n = 3). Statistical analysis
was performed using one-tailed Student’s t-test; * indicates significant difference
between cells cultured in hESC media and MSC media (p<0.05).
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media showed a significant decrease in the expression of SOX3 compared to cells
maintained in hESC media (Figure 3.13B), suggesting the possible suppression of
neuroectodermal lineage potential. Nonetheless, SOX17-ERT2 cells cultured in MSC
media showed no sign of spontaneous differentiation based on the analyses performed.

3.5.

Islet-regenerative

MSC-conditioned

media

promoted

PANC-1

cell

proliferation in vitro
Previous studies characterizing the islet-regenerative potential of human bonemarrow derived MSCs were performed using MSCs expanded in culture conditions
containing bovine serum [121,126]. Since bovine serum is known to induce the
spontaneous differentiation of hESCs, MSCs were propagated in serum-free media to
generate conditioned media (CM) for hESC experiments. Consequently, we assessed
whether MSC retained their proliferation-inducing characteristics when cultured under
serum-free conditions based on their previously established ability to promote the
proliferation of PANC-1 human pancreatic carcinoma cells in vitro [121]. As previously
observed under serum containing conditions [121], PANC-1 cells showed a significant
induction in cell proliferation when cultured in CM generated by regenerative MSC
compared to non-regenerative MSC, serum-free MSC media controls, or PANC-1 cell
basal media (DMEM + 10% bovine serum) (Figure 3.14B). Thus, conditioned media
generated from regenerative MSCs generated under serum-free conditions retained
proliferative-inducing capacity on PANC-1 cells in vitro.
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Figure 3.14. Islet-regenerative MSC-conditioned media promotes PANC-1 cell
proliferation. A) Representative images of regenerative and non-regenerative MSC
morphology 24h after passaging (passage 4). Scale bar equals 100 µm. B) PANC1 cell
proliferation as quantified using the Cyquant cell proliferation assay. PANC-1 cells were
cultured in either basal media (DMEM + 10% FBS; positive control), unsupplemented
MSC media (negative control), MSC serum-free media or MSC-conditioned media from
regenerative or non-regenerative MSCs. Data are presented as the mean ± SEM (n = 4).
Statistical analysis was performed using one-way ANOVA with Tukey’s multiple
comparisons post-hoc test. Statistical significance (p<0.05) is indicated by the use of
different letters between groups; same letters indicate that groups are not significantly
different from each other.
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3.6.

Culture of SOX17-ERT2; PB-NGN3 cells in regenerative MSC-CM does not

promote pancreatic endocrine maturation
In order to assess the effects of islet regenerative MSC-CM on endocrine cell
differentiation in vitro, SOX17-ERT2; PB-NGN3LOW and SOX17-ERT2; PB-NGN3HIGH
cells were cultured in regenerative MSC-CM, non-regenerative MSC-CM or basal MSC
media alone during NGN3-mediated specification of SOX17-DE progenitors. The
expression of genes associated with pancreatic endocrine development and function were
subsequently quantified by qRT-PCR. We first assessed differentiation when SOX17ERT2; PB-NGN3 cells were cultured in MSC-CM (or control conditions) from days 3-12
of NGN3 induction, following 5 days of SOX17-mediated DE differentiation. SOX17ERT2; PB-NGN3LOW cells cultured in islet-regenerative MSC-CM from days 3-12 of
NGN3 induction did not show induction of markers of pancreatic endocrine cell
maturation such as PDX1, ISL1, INS or SST compared to cells maintained in nonregenerative MSC-CM or MSC media alone (Figure 3.15). In fact, we observed a
significant reduction of NKX6.1 and SST gene expression in regenerative MSC-CM
culture when compared to NGN3-induction alone, suggesting suppression of endocrine
differentiation (Figure 3.15). Similarly, SOX17-ERT2; PB-NGN3HIGH cells cultured in
islet-regenerative MSC-CM from day 3 to day 12 of culture did not significantly alter the
expression of pancreatic endocrine markers compared to cells maintained in nonregenerative MSC-CM or MSC media alone (Figure 3.16).
We next assessed the effects of islet regenerative MSC-CM on SOX17-ERT2; PBNGN3 cell differentiation during later stages of NGN3 induction (conditioned media
added at days 6-12 or at days 9-12). Interestingly, SOX17-ERT2; PB-NGN3LOW cells

70

Figure 3.15. Culture of SOX17-ERT2; PBNGN3LOW cells in regenerative MSC
conditioned media (CM) does not promote pancreatic endocrine maturation. Real
time-PCR analysis of genes associated with pancreatic endocrine development and
function over 12 days of NGN3 induction post SOX17-mediated DE differentiation
(indicated as day 0). Cells were cultured in regenerative MSC-CM (green lines), nonregenerative MSC-CM (blue lines), or MSC media alone (black lines) during days 3 to 12
of NGN3 induction. Levels of gene expression are compared to those from transgenemediated cell differentiation under standard conditions (data duplicated from Figure 3.5
to facilitate direct comparison). A) markers of pancreatic endocrine differentiation, B)
markers of β and/or δ cell fates, C) marker of pancreatic ductal epithelia, and D)
pancreatic hormones (INS, GCG, SST) and the exocrine marker (AMY). Gene expression
is corrected for input based on expression of GUSB and expressed relative to
undifferentiated hESC (value set to 1). Data are presented as mean ± SEM (n = 3).
Statistical analysis was performed using two-way ANOVA with Tukey’s multiple
comparisons post-hoc test. X indicates significant difference (P<0.05) at each time point
between culture conditions.
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Figure 3.16. Culture of SOX17-ERT2; PBNGN3HIGH cells in regenerative MSC
conditioned media (CM) does not promote pancreatic endocrine maturation. Real
time-PCR analysis of genes associated with pancreatic endocrine development and
function over 12 days of NGN3 induction post SOX17-mediated DE differentiation
(indicated as day 0). Cells were cultured in regenerative MSC-CM (green lines), nonregenerative MSC-CM (blue lines), or MSC media alone (black lines) during days 3 to 12
of NGN3 induction. Levels of gene expression are compared to those from transgenemediated cell differentiation under standard conditions (data duplicated from Figure 3.5
to facilitate direct comparison). A) markers of pancreatic endocrine differentiation, B)
markers of β and/or δ cell fates, C) marker of pancreatic ductal epithelia, and D)
pancreatic hormones (INS, GCG, SST) and the exocrine marker (AMY). Gene expression
is corrected for input based on expression of GUSB and expressed relative to
undifferentiated hESC (value set to 1). Data are presented as mean ± SEM (n = 3).
Statistical analysis was performed using two-way ANOVA with Tukey’s multiple
comparisons post-hoc test. X indicates significant difference (P<0.05) at each time point
between culture conditions
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cultured in regenerative MSC-CM from days 9-12 of NGN3 induction showed a
significant upregulation of the early endocrine markers PAX6 and NKX6.1 when
compared to both the non-regenerative MSC-CM and MSC media controls (Figure 3.17).
Furthermore, NKX2.2 expression was significantly higher in islet regenerative MSC-CM
than non-regenerative MSC-CM (Figure 3.17). These data suggests that low NGN3
expressing cells are receptive to MSC-CM at later stages of differentiation. However, no
induction of mature endocrine markers PDX1, ISL1, INS or SST was observed (Figure
3.17). In fact, suppression of SST expression was observed following MSC-CM exposure
compared to transgene-mediated differentiation alone. This suggests that regenerative
MSC-CM promotes an early pancreatic precursor fate in SOX17-ERT2; PB-NGN3LOW
cells rather than directing functional endocrine maturation. Moreover, SOX17-ERT2; PBNGN3HIGH cells did not show significant changes in the expression of pancreatic
endocrine markers when exposed to regenerative MSC-CM either from days 6-12 or days
9-12 (Figure 3.18). Collectively these data suggest that factors secreted by isletregenerative MSCs did not efficiently promote endocrine maturation of SOX17-NGN3
pancreatic precursors.

73

Figure 3.17. Culture in the presence of regenerative MSC conditioned media (CM)
during later stages NGN3-mediated differentiation of SOX17-ERT2; PB-NGN3LOW
cells enhanced the expression of early pancreatic endocrine markers. Real time-PCR
analysis of regulatory genes of pancreatic endocrine development and function: A)
markers of pancreatic endocrine differentiation, B) markers of β and/or δ cell fates, C)
marker of pancreatic ductal epithelia, and D) pancreatic hormones (INS, GCG, SST) and
the exocrine marker (AMY) assessed following 12 days of NGN3 induction in the
presence or absence of MSC-CM. . Cells were cultured in regenerative MSC-CM (green
lines), non-regenerative MSC-CM (blue lines), or MSC media alone (black lines) for
either days 6-12 or days 9-12 of NGN3 induction. Levels of gene expression are
compared to those following 12 days of NGN3 induction under standard conditions (data
duplicated from Figure 3.5 to facilitate direct comparison). Gene expression is corrected
for input based on expression of GUSB and expressed relative to undifferentiated hESC.
Data are presented as the mean ± SEM (n=3). Statistical analysis was performed using
one-way ANOVA with Tukey’s multiple comparisons post-hoc test; * indicates statistical
difference between the culture conditions (p<0.05).
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Figure 3.18. Culture in the presence of regenerative MSC conditioned media (CM)
during later stages NGN3-mediated differentiation of SOX17-ERT2; PB-NGN3HIGH
cells enhanced the expression of early pancreatic endocrine markers. Real time-PCR
analysis of regulatory genes of pancreatic endocrine development and function: A)
markers of pancreatic endocrine differentiation, B) markers of β and/or δ cell fates, C)
marker of pancreatic ductal epithelia, and D) pancreatic hormones (INS, GCG, SST) and
the exocrine marker (AMY) assessed following 12 days of NGN3 induction in the
presence or absence of MSC-CM. Cells were cultured in regenerative MSC-CM (green
lines), non-regenerative MSC-CM (blue lines), or MSC media alone (black lines) for
either days 6-12 or days 9-12 of NGN3 induction. Levels of gene expression are
compared to those following 12 days of NGN3 induction under standard conditions (data
duplicated from Figure 3.5 to facilitate direct comparison).. Gene expression is corrected
for input based on expression of GUSB and expressed relative to undifferentiated hESC.
Data are presented as the mean ± SEM (n=3). Statistical analysis was performed using
one-way ANOVA with Tukey’s multiple comparisons post-hoc test; * indicates statistical
difference between the culture conditions (p<0.05).

75
CHAPTER 4:
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4.1.

NGN3 expression in SOX17-DEPs specifies endocrine cell fate
This study demonstrates that sequential activation of SOX17 and NGN3 in

pluripotent hESCs promotes pancreatic endocrine specification. During development, the
induction of NGN3 induces the expression of pancreatic endocrine transcription factors
including PAX4, PAX6, ISL1 and NKX6.1 [89]. Also, clonal cell lines with high levels of
ectopic NGN3 expression showed a significant induction in the mRNA expression of early
endocrine markers PAX4 and PAX6, and other markers implicated in β cell development
and function, NKX6.1 and PDX1. In contrast, clonal cell lines with lower levels of ectopic
NGN3 expression demonstrated a significant increase in the expression of known δ cell
markers CCKBR [40] and the hormone SST. However, we did not obtain convincing
staining characteristic of hormone localization for SST in SOX17-ERT2; PB-NGN3LOW
cells, suggesting that these cells are not functionally mature. In order to confirm our
immunocytochemistry results and to establish that SST protein is not being translated, a
more quantitative assessment of SST protein levels is required. Furthermore, induction of
GCG mRNA, a marker of α cell fate, or insulin protein was not observed in either NGN3expressing cell population. Collectively, these observations suggest that low level of
NGN3 expression guides SOX17-DEPs towards pancreatic endocrine precursors that
express δ cell-related genes, whereas higher levels of NGN3 expression in SOX17-DEPs
promotes the differentiation of pancreatic endocrine precursors that have a mRNA
expression profile more characteristic of early β cells.
Importantly, pancreatic differentiation in both clonal cell lines was not
homogeneous, with clusters of differentiated cells detected throughout the heterogeneous
cell populations. By immunocytochemistry, we consistently detected differentiated cells
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staining in areas of high cell density, suggesting that components of the cellular
microenvironment, such as paracrine signalling or cell-cell contact, may be influencing
cell differentiation. Cell microenvironment plays a critical role in cell differentiation.
Previous studies focusing on ectopic Pax4 expression in ES cells found enhanced cell
differentiation when cells were cultured in 3D spheroids [160]. It is therefore possible that
efficiency of our differentiation protocol may increase in 3D in vitro or in vivo culture
conditions. It is also noteworthy that since the SOX17/NGN3 cells demonstrated
continued cell proliferation, cells were passaged on day 5 of NGN3 induction in order to
obtain clear immunocytochemistry images and avoid over-confluent cultures at later
stages of differentiation. In contrast, cells were not passaged during the initial cell
differentiation experiments where mRNA expression patterns were being assessed,
meaning that cell density was significantly greater. If cell density does in fact influence
cell differentiation, the difference of cell density between the two experiments may
explain why we observed significant SST gene expression but we were unable to detect
convincing SST immunocytochemistry.
Previous studies in mouse pancreatic adenocarcinoma (mPAC) cells and mouse
pancreatic ductal epithelial cells (mPDEC) have demonstrated that the level of ectopic
Ngn3 expression influences the efficiency of differentiation towards the endocrine fate,
such that higher levels of Ngn3 expression results in greater proportions of differentiating
cells than lower levels [161]. Supporting these findings, qualitative assessment of our
immunocytochemistry data suggests that high NGN3 expression in SOX17-DEPs results
in greater proportions of PAX6 and ISL1-positive cells than low NGN3 expression.
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The expression of β cell markers after NGN3 induction in SOX17-ERT2; PBNGN3HIGH cells may be due to the early induction of PAX4. During development it has
been shown that PAX4 can promote the β cell fate [91], and repress the α-cell lineage
[162] in pancreatic endocrine progenitors. Apart from β cell fate specification, PAX4positive progenitors have been also been implicated in δ cell differentiation during
development [91]. However, we did not observe significant induction of PAX4 levels in
SOX17-ERT2; PB-NGN3LOW cells which showed a significant increase in the expressions
of δ cell-related genes upon NGN3 induction. Our findings are supported by studies
showing that PAX4 is not required for δ cell specification. Indeed, mice lacking
expression of both Pax4 and the α cell fate specification regulator Arx showed complete
depletion of α and β cells, resulting in a δ cell dominated pancreas [163]. This suggests
that Pax4 may serve more specifically to promote the β cell fate. Our study supports these
findings by showing that significant induction of PAX4 expression is not necessary for the
induction of SST-expression in the SOX17-ERT2; PB-NGN3LOW clone.
Although SOX17-ERT2; PB-NGN3HIGH cells showed a significant induction in the
mRNA expression of a known β cell marker PDX1, we did not observe a significant
induction of INS mRNA or protein. This suggests that these cells may represent β cell
precursors that are phenotypically and functionally immature. SOX17-ERT2; PBNGN3LOW cells showed significant SST gene induction. Importantly, in both cell lines we
observed a lack of NKX2.2 mRNA induction, which is an important transcription factor
for terminal differentiation of β cells [98] and repression of SST gene expression during
development [99]. The lack NKX2.2 induction in both clones may help to explain why
we observed more efficient induction of genes associated with δ cells than β cells.
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Although PDX1 is commonly used as a β cell marker [164,165], it is also
expressed in the developing gastric enteroendocrine cells [82,83]. Similarly, SST
expression is not pancreas-specific but is also found in endocrine cells of the stomach and
the intestine [166,167]. Therefore, we cannot rule out the possibility that NGN3 induction
in DEPs may be promoting the differentiation of other endoderm-derived endocrine cell
lineages. Future studies should focus on global mRNA expression analysis to better
assess the effects of NGN3-mediated differentiation on DEPs.
We detected some discrepancies when comparing our immunocytochemistry
results with mRNA expression analysis. For instance, we detected PAX6 and ISL1
protein expression in SOX17-ERT2; PB-NGN3LOW cells but we did not observe
significant induction in their mRNA expression during the course of NGN3 induction.
Also, for SOX17-ERT2; PB-NGN3HIGH cells we detected a subset of cells with
ISL1protein induction despite the lack of a significant change in mRNA expression. The
technical limitations associated with quantifying gene expression within a heterogeneous
population versus being able to identify and image subpopulations of cells expressing
candidate protein by immunostaining could explain these discrepancies.

In our

immunocytochemistry data we observe a mixed population of protein-positive and
negative cells. Since our mRNA analysis was performed on the total population of cells it
is likely that the mRNA expression of the population was not significant due to a large
proportion of non-differentiated cells. Furthermore, poor correlation of mRNA and
protein expression has been previously noted in literature. In fact, mRNA expression and
protein levels have a correlation coefficient of less than 0.4 [168]. Similar to our findings,
several studies have shown that protein levels do not correlate with transcript levels [169-
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172]. For instance, Tian et al.measured the expression of 425 proteins and mRNA in
multipotent mouse hematopoietic progenitor EML cells and their differentiated progeny.
This study mapped the protein expression to their corresponding mRNA expression and
showed that 35% of the genes investigated had significantly upregulated protein levels
but the mRNA expression remained unaltered [169]. Such discrepancies are primarily
due to post-transcriptional and translational regulation [168].

4.2.

The level of NGN3 influences endocrine cell fate determination.
Previous studies have shown that alterations in Ngn3 expression in vivo have

considerable effects on determination of endocrine versus exocrine cell fates. Endocrine
progenitors expressing reduced levels of Ngn3 adopted pancreatic ductal or acinar fates
while high levels of Ngn3 expression was reported to be critical for endocrine
commitment from multipotent pancreatic progenitors [173]. In addition, studies have
shown that the level of Ngn3 expression has a considerable impact on the expression of
downstream factors regulating endocrine differentiation. The transduction of a Ngn3
retroviral transgene in mouse pancreatic ductal epithelial cells (mPDEC) demonstrated
that Pax4 expression is linearly dependent on the level of Ngn3 expression [161]. We
observed a similar correlation between the level of ectopic NGN3 expression with the
mRNA expression of the early endocrine TFs PAX4 and PAX6 in SOX17-DEPs.
We suggest that the difference in the induction of early endocrine transcription
factors PAX4 and PAX6 influences the difference observed in the differentiation of high
and low NGN3 expressing SOX17-DEPs. Previous studies have suggested that Pax4 and
Pax6 orchestrate β cell differentiation, and that diminished levels of either of these
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factors, as observed in Pax4-null and Pax6-null mice, leads to the development of ghrelin
positive ε cells [174]. Based on our data, we suggest that the specific level of PAX4 and
PAX6 expression induced differentially regulates endocrine fate specification, where
lower levels of expression direct δ cell specification, whereas higher levels of expression
direct β cell specification.
Collectively, our data along with previous studies show that the level of NGN3
expression significantly impacts the expression of downstream endocrine transcription
factors. These findings may be related to the short half-life of the Ngn3 protein associated
with post-translational ubiquitin-mediated degradation [175], and thus high levels of
transcription and protein production may be critical for maintaining sufficient
bioavailability for transcriptional activity.
In order to improve our understanding of the effects of NGN3 expression on
endocrine differentiation, future studies should more thoroughly characterize the
phenotype of SOX17-ERT2; PB-NGN3LOW/HIGH cells by whole transcriptome analyses.
Furthermore, to assess the biological activity of NGN3, chromatin immunoprecipitation
with parallel DNA sequencing (ChIP-sequencing) could be performed for cell lines with
different levels of NGN3 expression to identify direct NGN3 targets. This global
characterization would provide a better understanding of the interplay between NGN3
DNA binding, dose and bioavailability.
Considering that previous studies aimed at generating pancreatic cells from
pluripotent human cells show an improvement in the efficiency of endocrine
differentiation after transplantation in vivo [130], it would also be informative to compare
the in vivo differentiation of SOX17-ERT2; PB-NGN3LOW/HIGH cells using standard
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teratoma assays or recently developed protocols for intra-pancreatic injection in NODSCID mouse models after streptozotocin-induced deletion of endogenous β cells
[121,126].

4.3.

Islet-regenerative MSCs conditioned media did not promote maturation of

NGN3-positive endocrine precursors
The current study also aimed to capitalize on previous studies by our group
showing that certain human bone-marrow derived MSC samples were able to induce new
islet

formation

following

transplantation

into

STZ-treated

NOD/SCID

mice

[121,126,146], while other BM MSC samples were not [121]. We hypothesized that
paracrine factors secreted by islet regenerative MSC samples would promote the
maturation of SOX17-NGN3 pancreatic endocrine precursors towards the β cell fate.
However, our data shows that islet-regenerative MSC-CM did not direct NGN3expressing precursors to a mature phenotype in vitro. One potential explanation may be
that additional factors or cell-cell contact present in vivo may be required to direct
terminal differentiation. This is supported by previous studies that demonstrate the
generation of insulin secreting cells from hESC only happens following in vivo
maturation of cells [130]. It is also possible that the NGN3-positive precursors generated
in these studies may not be responsive to islet regenerative MSC secreted factors.
Previous studies have shown that NGN3-positive progenitors were not detected at
specific time points during MSC-induced islet-regeneration [126], suggesting that
paracrine factors secreted by regenerative MSCs may not act through an NGN3-positive
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precursor cell or NGN3 expression was not induced in endogenous adult pancreatic cells
as part of the islet-regenerative process.
Furthermore, other studies have also suggested that CK19-positive ductal
pancreatic progenitor cells may represent primary effectors implicated in adult islet
neogenesis [176,177]. Indeed, MSC-induced islet formation was associated with ductal
structures, and these small neoislets contained CD19+ cells as evidence of ductal cell
involvement in the regenerative process [121,126]. Alternatively, MSC secreted factors
may act on a more differentiated endocrine precursor cell that has already reduced NGN3
expression and gained CK19 expression. Interestingly, the SOX17-ERT2; PB-NGN3LOW
cells, which demonstrated induction of early pancreatic endocrine markers after culture
with islet-regenerative MSC-CM during the later stages of NGN3 induction (days 9-12),
were also found to express CK19 at this later stage of differentiation. In contrast, SOX17ERT2; PB-NGN3HIGH cells that do not express CK19 did not show changes in pancreatic
endocrine markers expression following exposure to islet-regenerative MSC-CM.
Therefore, similar to the in vivo tissue repair response, CK19-expressing SOX17-ERT2;
PB-NGN3 cells may be more receptive to paracrine factors secreted by islet-regenerative
MSCs. However, it is possible that CK19 does not co-localize with other endocrine
markers (PAX6, ISL1), and may represent a distinct cell population. Protein colocalization studies should be performed to understand the context of CK19 expression
during NGN3-mediated differentiation of DEPs.
Importantly, the complete mechanism associated with MSC-induced isletregeneration in vivo has yet to be determined; however the results from the current study
suggest that the factors that promote islet-regeneration in vivo may be distinct from the
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factors required to promote functional maturation of hESC-derived NGN3-positive
endocrine precursors. For instance, islet-regenerative MSCs have been shown to possess
pro-angiogenic and anti-inflammatory potential [126], that may be important in inducing
islet-regeneration in whole organ systems in vivo, but may not be relevant to promote
pancreatic endocrine maturation of DEPs. Therefore, we propose that better
understanding of the mechanisms by which islets are formed during development and
during MSC-induced islet regeneration is required before achieving the ultimate goal of
generating an unlimited number of functional β cells from pluripotent sources.

4.4. Limitations of the Study and Future Directions
There are several potential limitations associated with the use of conditioned
media to recreate the MSC-mediated islet-regenerative microenvironment. First is the
likelihood that short-term factors and cytokine secreted into the CM were degraded due
to freezing of the conditioned media prior to experimentation. Alternatively, direct cellcell contact between MSC and pancreatic progenitors may be required for the islet
neogenesis characterized in vivo. As a consequence, a complete recreation of in vivo
regenerative microenvironment may not be possible using CM. In order to tackle these
limitations, future experiments should focus on direct co-culture of MSCs and putative
endocrine precursors to better assess the effects of islet-regenerative factors on
maturation of endocrine precursors. Finally, the in vitro monolayer culture used in these
studies does not mimic the in vivo 3D environment that may contribute to the maturation
of SOX17-NGN3 pancreatic precursors. Therefore, these experiments should be repeated
in vivo using co-transplantation of regenerative MSCs and NGN3-positive precursors.
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This will test the effects of MSC-maturation signals in a 3D in vivo environment enabling
a direct comparison with the in vitro experiment conducted in this study.
Additionally, the protocol developed for transcription factor-mediated pancreatic
endocrine specification from DEPs skips two key developmental stages that follow
endoderm specification during embryonic development: primitive foregut gut
specification [61] and PDX1-mediated pancreas specification [76], which occur before
the initiation of NGN3-mediated endocrine differentiation [62]. Therefore, future
experiments should investigate the effects of sequential induction of PDX1 then NGN3 in
SOX17-DEPs in order to formulate a more efficient transcription factor based protocol
for differentiating stable and mature endocrine cells from pluripotent stem cells.

4.5.

Conclusion and Summary
The current study demonstrated that NGN3 activation after SOX17-mediated

DEP specification in hESC promotes step-wise induction of transcription factors
important for pancreatic endocrine differentiation. We also show NGN3-mediated
differentiation to be dose-dependent, with low levels of NGN3 expression promoting δ
cell-like characteristics, and high expression of NGN3 promoting the induction of some β
cell-like characteristics. Moreover, we found that these endocrine progenitor populations
were not responsive to signals secreted by islet-regenerative MSCs, suggesting that
microenvironmental regulators of islet regeneration after injury and the normal
development of NGN3-positive progenitor cells may be distinct.
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Appendix
Appendix 1. Immunocytochemistry positive control experiments. Staining of βTC6
cells (an insulin-secreting cell line derived from transgenic mice expressing the large Tantigen of simian virus 40 (SV40) in pancreatic β cells as a positive control for endocrine
markers: PAX6, ISL1 and NGN3. Scale bar equals 100 µm.
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Appendix 2. Immunocytochemistry negative control experiments. Staining only with
secondary antibodies used in this study. Scale bar equals 100 µm.
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